

350 5<sup>th</sup> Avenue  
New York, New York  
10118

May 6, 2019

Governor Kate Brown  
Office of the Governor  
900 Court Street NE, Suite 254  
Salem, OR 97301-4047  
Phone: (503) 378-4582



HRW.org

CC: Tina Edlund, Health Policy Advisor to Gov. Brown; Dr. Dana Hargunani; HERC members

Dear Governor Kate Brown,

We are writing to express our serious concern over a policy proposed by Oregon's Health Evidence Review Commission (HERC) that would mandate involuntary opioid dose reductions for Medicaid patients with some chronic pain conditions. This practice is not encouraged by any medical or professional guidelines because it can destabilize patients' physical and mental health. While we believe that the overprescribing of opioids has caused great harm, policy solutions like this one risk hurting patients, as the Centers for Disease Control and Prevention (CDC) underscored in recent statements opposing mandatory dose reductions. We urge you to call on HERC to vote against this proposal on May 16 in an effort to prevent the unnecessary suffering of tens of thousands of vulnerable Oregonians.

Human Rights Watch has documented the dangers of involuntary opioid dose reductions. [In a December 2018 report](#), we found that patients who had benefited from long-term opioids were nonetheless being forced to lower doses by their physicians, who feared liability or regulatory oversight. [While studies show](#) that patients' health can improve when they choose to lower their dose voluntarily, the opposite appears to be the case for those tapered without their consent: HRW found that patients could no longer work, support loved ones, or in some cases even go to the toilet unassisted. Patients also felt increasingly isolated, [contemplated suicide](#), and in some cases, turned to illicit drugs or alcohol.

[The HERC's proposal](#) continues to promote the involuntary tapering of patients with neck, back, and spine conditions as well as fibromyalgia — in total, more than 170 diagnoses. While we commend HERC for certain revisions to this policy, including allowing providers to slow or temporarily stop a taper, ultimately, the policy still mandates involuntary dose reductions for a broad class of patients, and therefore still risks doing serious harm. Even if treatment options are expanded, opioids are an essential medication and, so long as they are prescribed

Kenneth Roth, Executive Director

Deputy Executive Directors

Michele Alexander, Development and Global Initiatives

Nicholas Dawes, Media

Iain Levine, Program

Chuck Lustig, Operations

Bruno Stagno Ugarte, Advocacy

Emma Daly, Communications Director

Dinah PokKempner, General Counsel

James Ross, Legal and Policy Director

Division and Program Directors

Brad Adams, Asia

Nicole Austin-Hillery, United States

Mausi Segun, Africa

José Miguel Vivanco, Americas

Sarah Leah Whitson, Middle East and North Africa

Hugh Williamson, Europe and Central Asia

Shantha Rau Barriga, Disability Rights

Peter Bouckaert, Emergencies

Zama Neff, Children's Rights

Richard Dicker, International Justice

Bill Frelick, Refugees' Rights

Arvind Ganesan, Business and Human Rights

Liesl Gernholtz, Women's Rights

Steve Goose, Arms

Diederik Lohman, Health and Human Rights

Marcos Orellana, Environment and Human Rights

Graeme Reid, Lesbian, Gay, Bisexual, and Transgender Rights

Advocacy Directors

Maria Laura Canineu, Brazil

Louis Charbonneau, United Nations, New York

Kanae Doi, Japan

John Fisher, United Nations, Geneva

Meenakshi Ganguly, South Asia

Bénédicte Jeannerod, France

Lotte Leicht, European Union

Sarah Margon, Washington, DC

David Mepham, United Kingdom

Wenzel Michalski, Germany

Elaine Pearson, Australia

Board of Directors

Hassan Elmasry, Co-Chair

Robert Kissane, Co-Chair

Michael Fisch, Vice-Chair and Treasurer

Oki Matsumoto, Vice-Chair

Amy Rao, Vice-Chair

Amy Towers, Vice-Chair

Catherine Zennström, Vice-Chair

Bruce Rabb, Secretary

Karen Herskovitz Ackman

Akwasi Aidoo

Jorge Castañeda

George Coelho

Natasha Dolby

Kimberly Marteau Emerson

Lawton Fitt

Leslie Gilbert-Lurie

Paul Gray

Caitlin Heising

Betsy Karel

David Lakhdhir

Alicia Miriana

Joan R. Platt

Neil Rimer

Shelley Frost Rubin

Ambassador Robin Sanders

Sidney Sheinberg

Bruce Simpson

Joseph Skrzynski

Donna Slaight

Siri Stolt-Nielsen

Darian W. Swig

Susan Kane Walkush

Marie Warburg

appropriately, should continue to be an option for those with these painful conditions.

No medical or professional guidelines recommend tapering patients off opioid medications involuntarily. Some guidelines, such as the [CDC guideline](#) on opioid prescribing issued in 2016, have been misinterpreted as supporting such practices. But last week, three authors of the guideline wrote in [The New England Journal of Medicine](#) that it “does not address or suggest discontinuation of opioids already prescribed at higher doses.” The authors wrote that while some patients may succeed with a dose reduction, “other patients may find tapering challenging” or “have adverse psychological and physical outcomes.” Ultimately, the CDC authors concluded, “policies should allow clinicians to account for each patient’s unique circumstances in making clinical decisions.” This article was accompanied by a [press release from the CDC](#), as well as a [statement from the CDC Director](#) on April 10 noting that the guideline “does not endorse mandatory or abrupt dose reduction or discontinuation, as these actions can result in patient harm.”

Unfortunately, Oregon’s proposed policy would fly the face of these recent CDC clarifications. While the policy claims to be patient-centered, it would in fact tie doctors’ hands and force them to enact dose reductions against their better clinical judgment, even when they destabilize a patient physically or mentally. Indeed, Oregon’s proposal is more extreme than any in the nation both because it mandates the full discontinuation of opioids – a taper to zero – and it does so for a broad class of patients. We commend Oregon for its willingness to make non-opioid treatments, and particularly non-pharmacological treatments, more widely available to Medicaid patients. But while the scientific evidence shows that these treatments can be a useful tool to some patients, there is no indication that providing these services in the context of a forced taper can replace opioids or prevent the harm associated with mandated tapers.

Medical experts and advocates have repeatedly brought these arguments to the attention of the Oregon Health Authority, HERC, and other state officials: most recently, [a letter from more than 100 leading physicians and other experts](#) found that there is no evidence available to suggest that this policy would protect patients from harm, and no evidence to support the decision to target patients with the aforementioned diagnoses. The HERC itself found that there was “insufficient evidence” regarding the harms or the safety of involuntary tapering – and yet it has endorsed a policy that would mandate this practice. Now that the CDC has also come out against mandatory tapers and policies that misapply its guideline, we hope that Oregon will reconsider.

We call on the Governor to urge the Health Evidence Review Commission not to pass this dangerous and ill-conceived policy on May 16, and to include opioid therapy as a treatment option for all pain conditions addressed in this proposal. The lives of tens of thousands of Oregonians – who could suffer from increased pain, disability, suicide, or overdose as a result of this policy – are at stake.

Sincerely,

Laura Mills

Researcher

Health and Human Rights

Human Rights Watch

[www.hrw.org](http://www.hrw.org)

millsl@hrw.org